NCT07409896 Comparison of Anesthetic Efficacy OF 2% Lidocaine Inferior Alveolar Nerve (IANB) Block Versus Primary Buccal Infilteration With 4% Articaine in Symptomatic Irreversible Pulpitis(SIP) IN Mandibular First Molars
| NCT ID | NCT07409896 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Armed Forces Institute of Dentistry, Pakistan |
| Condition | Anesthetic Efficacy |
| Study Type | INTERVENTIONAL |
| Enrollment | 330 participants |
| Start Date | 2026-03-20 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 330 participants in total. It began in 2026-03-20 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled trial aims to compare the anesthetic efficacy of 2% lignocaine administered through an inferior alveolar nerve block (IANB) in one group of participants with 4% articaine delivered via primary buccal infiltration in other group in patients with symptomatic irreversible pulpitis in mandibular first molars.
Eligibility Criteria
Inclusion Criteria: * Systemically healthy patients classified as ASA I, aged 18-55 years. * Permanent mandibular first molar tooth requiring endodontic therapy. * Diagnosed with symptomatic irreversible pulpitis without swelling or sinus. * Normal periapical radiographic appearance (no evidence of periapical pathology). * Moderate pain as assessed by the Heft-Parker VAS (\>54 mm and \<114 mm). * Lingering pain or prolonged response to cold testing (lasting more than 10 seconds). * Positive response to electric pulp testing. * Outcome assessed must be pulpal anesthesia Exclusion Criteria: * • Pregnant or lactating mothers. * Teeth with reversible pulpitis, previously treated, or with calcified canals. * Teeth with severe periodontal disease or periapical radiolucency. * Patients who have taken analgesics or anti-inflammatory drugs within 6 hours before the treatment visit. * Patients on medications that could potentially interact with the anesthetic solution (e.g., antihypertensives, anticoagulants). * History of allergy to 4% articaine, lidocaine, or epinephrine. * Systemic diseases, immunocompromised states, or significant anxiety/mental health disorders. * History of vasovagal syncope on local anesthetic administration
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07409896 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Anesthetic Efficacy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07409896 currently recruiting?
Yes, NCT07409896 is actively recruiting participants. Contact the research team at sadiashehzadi321@gmail.com for enrollment information.
Where is the NCT07409896 trial being conducted?
This trial is being conducted at Rawalpindi, Pakistan.
Who is sponsoring the NCT07409896 clinical trial?
NCT07409896 is sponsored by Armed Forces Institute of Dentistry, Pakistan. The trial plans to enroll 330 participants.